COMPARATIVE STUDY OF GLIMEPIRIDE AND GLICLAZIDE IN TYPE 2 DIABETES PATIENTS ON SAFETY, EFFICACY AND TOLERABILITY

Abstract

Background and Objective: Impaired glucose tolerance and impaired fasting glycaemia are risk categories for future development of diabetes and cardiovascular disease. Apart from being the leading cause of renal failure, it also increases the risk of lower limb amputations, visual impairment and tuberculosis. Higher incidence of Diabetes Mellitus in the last decade has compelled us to conduct the present study with an objective to establish safety, efficacy and tolerability of gliclazide against glimepiride in the treatment of type 2 Diabetes Mellitus.

Methodology: The present study was single centered, prospective and observational conducted after obtaining approval from the ethics committee. A total of 40 patients who visited the outpatient block of Apollo hospital at Jubilee Hills, Hyderabad were enrolled in the study. A questionnaire was used to record the response of subjects participated in the study.

Results: A higher proportion of patients belonged to the age group of 41-50 years. Gliclazide did not result in any ADR while glimepiride caused eight ADRs. Average reduction of FBS and PPBS in gliclazide group was found to be 52.5% and 41.3% respectively. Corresponding figures for glimepiride were 56.9% and 32.3%. HbA1c reduction in gliclazide and glimepiride group was 2.44 and 1.91 respectively. Both drugs were found to be well tolerated by the patients.

Conclusion: Gliclazide was found to be superior in terms of safety and efficacy. Hence it can be concluded from the study that gliclazide is a better option in diabetes when compared to glimepiride.

Keywords: diabetes mellitus, efficacy, gliclazide, glimepiride, safety, tolerability